| Zacks Company Profile for Insmed, Inc. (INSM : NSDQ) |
|
|
| |
| • Company Description |
| Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
Number of Employees: 1,271 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $98.24 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 6,140,144 shares |
| Shares Outstanding: 189.71 (millions) |
| Market Capitalization: $18,637.36 (millions) |
| Beta: 0.90 |
| 52 Week High: $106.83 |
| 52 Week Low: $60.40 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
33.31% |
27.82% |
| 12 Week |
45.43% |
27.44% |
| Year To Date |
42.29% |
34.39% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
William H. Lewis - Chair and Chief Executive Officer
Sara Bonstein - Chief Financial Officer
David R. Brennan - Lead Independent Director
Alfred F. Altomari - Director
Elizabeth McKee Anderson - Director
|
|
Peer Information
Insmed, Inc. (CORR.)
Insmed, Inc. (RSPI)
Insmed, Inc. (CGXP)
Insmed, Inc. (BGEN)
Insmed, Inc. (GTBP)
Insmed, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 457669307
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 189.71
Most Recent Split Date: 3.00 (0.10:1)
Beta: 0.90
Market Capitalization: $18,637.36 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-1.28 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-5.26 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 10.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
